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Abstract
Performed in an outpatient, office-based setting, dermatologic surgery reduces 
healthcare costs of hospitalization while maintaining low rates of surgical com-
plications such as infection, dehiscence, and hematoma formation. However, the 
potential for complications requiring hospitalization or IV antibiotic therapy still 
exists and varies depending on patient risk factors, such as the use of antiplatelet 
and anticoagulant medications. Furthermore, measured outcomes in dermatologic 
surgery expand beyond surgical wound complications to include optimization of 
wound healing and reduction of scar formation, especially in cosmetically sensitive 
areas of the body. Biosurgical agents are increasingly being used in surgical fields to 
achieve hemostasis and to optimize wound healing. This chapter reviews the typical 
methods to achieve hemostasis in dermatologic surgery and examines the current 
and future role of biosurgical agents in procedural dermatology.
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1. Introduction
Dermatologic surgery includes office-based procedures such as skin biop-
sies, excision, desiccation and curettage, and Mohs micrographic surgery [1]. 
Intraoperatively, achieving adequate hemostasis is important to clear the surgical 
field. Postoperatively, hemostasis is necessary to decrease the risk of dehiscence, 
hematoma formation, and infection, while optimizing wound healing and scar-
formation. Factors that influence the choice of hemostatic agent include location, 
wound size, and amount of bleeding [2]. Other factors that influence hemostasis 
include the patient’s medical history, medications, and the inherent qualities of 
the skin at the site of the surgery. The use of antiplatelet or anticoagulant medica-
tions may decrease the efficacy of some hemostatic agents. Concurrent medical 
disease such as liver cirrhosis can lead to alterations in platelets and the coagulation 
pathways. Elderly patients are more likely to have fragile skin as a result of chronic 
sun damage, and make up much of the population on antiplatelet and anticoagula-
tion agents.
Many methods exist to achieve hemostasis intra- and post-operatively. These 
include topical hemostatic agents, adhesives, electrosurgery, sutures, and biologic 
agents. This chapter provides an overview of the methods to achieve hemostasis and 
of the use of biosurgical agents in dermatologic surgery.
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2. Physiologic hemostasis
An understanding of physiologic hemostasis is necessary to determine what 
hemostatic agent is most appropriate. Physiologic hemostasis occurs via three 
stages: initiation, amplification and propagation [1]. The initiation phase involves 
endothelial injury leading to exposure of tissue factor (TF) [1]. The exposed TF 
binds and activates Factor VII, and the resultant complex activates Factors X and 
IX, ultimately leading to formation of Factor II (thrombin) [1]. This mechanism of 
endothelial injury leading to coagulation is also known as the intrinsic pathway to 
achieve hemostasis [1].
Simultaneously, exposure of endothelial collagen begins the amplification stage. 
Circulating von Willebrand factor (vWF) binds to exposed collagen on one end and 
attracts platelets at the other end. Meanwhile, the thrombin that was created in the 
initiation phase will activate these platelets, stimulating release of clotting factors 
and for increased production of thrombin [1].
In the final, propagation phase, thrombin converts fibrinogen to fibrin into a 
network that stabilizes the platelet clot in a manner that is calcium dependent [1]. 
Thus, the induction of endothelial injury results in hemostasis via the interaction of 
multiple coagulation factors creating a platelet clot.
Impairments in hemostasis may be genetic or inherent to the patient and can 
involve any step of the pathway described above. One example of a bleeding 
diathesis is the genetic lack of coagulation Factor VIII leading to hemophilia A 
[1]. These patients have a prolonged bleeding time and can have large hematomas 
as a result of minor injuries. When patients are on antiplatelet and anticoagulant 
medications such as aspirin or warfarin, respectively, the duration of bleeding 
is prolonged because of a therapeutic and desired reduction in clot formation. 
Although these medications are continued for routine dermatologic surgery, such 
factors must be taken into account when determining appropriate methods of 
hemostasis.
3. Methods to achieve hemostasis
3.1 Mechanical agents
One of the simplest methods to achieve hemostasis is mechanical compression 
[1]. Application of pressure to the capillaries results in platelet aggregation and 
thrombus formation [2]. Mechanical compression is routinely used in the dermatol-
ogy clinic for superficial wounds such as following a biopsy procedure. It is less 
useful in the intraoperative setting to acutely reduce bleeding. Temperature regula-
tion can also induce hemostasis. The vasoconstriction caused by decreasing the 
temperature of the tissue will decrease the rate of bleeding. However, there is a risk 
of tissue damage and rebound vasodilation [2].
3.2 Physiologic agents
Physiologic agents utilize the body’s inherent mechanisms to control the rate 
of bleeding. Epinephrine, frequently mixed with local anesthetics for use in 
dermatologic procedures, induces vasoconstriction [2]. The rare side effect of 
tachyarrhythmia is usually seen with systemic use [2] and can be safely avoided 
by local injection. One side effect that may be seen in dermatologic procedures is 
postoperative bleeding following rebound vasodilation once the effects of epi-
nephrine have worn off [2]. Cocaine is another vasoconstrictor that may decrease 
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bleeding, but it is rarely used dermatology due to its side effect profile and high 
potential for illicit use [2].
When applied to wounds, tranexamic acid causes competitive inhibition of the 
activation of plasminogen [2]. This results in decreased levels of plasmin, which 
functions to break down fibrin clots. Therefore, tranexamic acid decreases bleed-
ing by reducing the breakdown of clots. It is easy to apply topically in the setting 
of dermatologic procedures [2]. Hydrogen peroxide is easily available and has mild 
hemostatic properties by enhancing platelet aggregation [2]. It has antimicrobial 
properties and plays a role in wound care [2]. One downside to its use is inhibition 
of wound healing [2].
3.3 Biologic agents
Biologic agents influence the coagulation cascade to enhance clot formation. 
Most involve thrombin and fibrin [2], two important steps in the coagulation cas-
cade. As described in the “Hemostasis” section, the coagulation cascade results in 
the formation of thrombin. Thrombin is essential to convert inactive fibrinogen to 
fibrin, which forms a mesh-like network with platelets and creates a stable platelet 
plug at the site of endothelial injury. This platelet plug is resistant to degradation 
until purposely broken down by plasmin. In biologic agents used for hemostasis, 
the concentration of thrombin determines the speed of clot formation and tensile 
strength [2]. The concentration of fibrinogen determines the mechanical strength 
[2]. There are four major types of biologic agents: thrombin, fibrin sealants, hemo-
static matrix, and platelet gels and sealants [2].
Thrombin can be applied by itself and is available in a variety of forms including 
spray, liquid, hypodermic injection, or saturation of gauze or sponge [2]. It is useful 
in patients who are on antiplatelets and anticoagulants [2] because it provides the 
necessary thrombin to locally activate fibrinogen to fibrin at the site of the surgical 
wound. It can also be left within the surgical wound as the resulting fibrin clot will 
be reabsorbed over time [2]. Although there are recombinant forms, many throm-
bin agents are bovine- or human-derived and therefore have antigenic potential i.e. 
an associated risk of antibody formation [2]. It can also induce diffuse intravascular 
coagulation (DIC) if it is given in large enough quantities to cause systemic absorp-
tion or if it is erroneously injected into the circulatory system [2]. Cost may be a 
limiting factor [2].
Hemostatic matrix combines thrombin and gelatin but must be removed from 
the wound following hemostasis [2]. Thrombin and hemostatic matrix rely on 
fibrinogen present in blood [2]. They are not useful in patients with afibrinogen-
emia as they activate the patient’s circulating fibrinogen [2]. Hemostatic matrix can 
become difficult to use after three minutes following preparation [2]. Fibrin seal-
ants contain both thrombin and fibrinogen but require preparation of the wound 
bed as they are denatured by antiseptics [2]. Fibrin sealants also require stirring and 
heating prior to application [2]. Platelet gels and sealants contain bovine collagen 
and thrombin and can be used in reconstructive surgery [2]. They require operator 
skill for preparation and have a high cost and antigenic potential [2]. These products 
are unique in that they act as hemostatic agents, create a waterproof barrier and 
function as a tissue adhesive [2]. However, use of fibrin sealants for routine derma-
tologic surgery is cost-prohibitive [1].
3.4 Chemical agents
Chemical agents are caustic substances that create a localized destruction of 
tissue to cause thrombus formation and include zinc paste, Monsel’s solution, silver 
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nitrate and aluminum chloride [2]. Zinc paste is rarely used in dermatology as it 
causes irritation and pain and cannot be used in wounds that will ultimately be 
closed [2]. Monsel’s solution is an acidic solution that oxidizes when exposed to 
air [2]. There is an increased risk of dermal fibrosis and inflammation, along with 
dyspigmentation from the deposition of iron particles into the dermis that may 
confuse the clinical picture if considering re-excision [2]. Silver nitrate presents a 
similar but much rarer risk of tattoo formation due to the deposition of silver par-
ticles [2]. The precipitant obstructs blood vessels and leads to eschar formation [2]. 
However, the formation of eschar may result in tissue damage and impaired wound 
healing, and patients typically experience stinging on application [2]. Aluminum 
chloride leads to the hydrolysis of hydrogen chloride and leads to coagulation via 
constriction of blood vessels and activation of the extrinsic pathway [2]. Its cost is 
affordable, and it is commonly used in dermatology for small wounds left to heal by 
secondary intention [2]. Monsel’s solution, silver nitrate and aluminum chloride are 
also easy to store [2].
3.5 Physical agents
All physical agents have absorptive properties that remove fluid while leaving 
behind concentrated coagulants [2]. When applied to the wound, they create a 
three-dimensional meshwork where platelets aggregate and form a clot [2]. The 
physical agent absorbs blood during this process. These are practical and cost-
effective for dermatologic surgery [1]. They include gelatin, cellulose, microfibrillar 
collagen, and hydrophilic polymers.
When applied to the wound, gelatin increases to twice its size but can also cause 
compression of nearby structures if the site is closed [2]. Wounds left to heal by 
secondary intention are not confined and gelatin can be applied for hemostasis 
without the risk of compression [2]. Gelatin is available in a variety of forms with 
brand names such as “Gelfoam”, “Gelfilm” and “Surgifoam” [2]. It is relatively 
affordable, nonantigenic in tissue, and can be left inside the wound during closure 
[2]. It is useful in the setting of small vessel bleeding commonly encountered in 
dermatologic procedures [2].
Cellulose is able to absorb up to seven times its weight [2]. It is available in mesh, 
fiber, and powder form [1]. It is applied to the wound and is ultimately broken-
down during healing [1], but its slow absorption increases the risk for foreign body 
reactions [2].
Microfibrillar collagen causes binding of clotting factors to the physical matrix 
and is available in a powder, sheets, and fleece forms [2]. However, it is dependent 
on platelet activation and is less effective if patients are thrombocytopenic [2]. It 
is effective in patients on heparin therapy and is normally used on large surface 
areas [2]. In contrast, hydrophilic polymers do not rely on the clotting cascade and 
are useful in patients on anticoagulants [2]. Hydrophilic polymers are not metabo-
lized by the body and can only be used in wounds left open to heal by secondary 
intention, or they may be used temporarily for hemostasis before final wound 
closure [2].
3.6 Synthetic, mechanical adhesives
Cyanoacrylates are synthetic acrylates that rapidly polymerize to form a water-
resistant barrier [2]. These can be applied to low-tension cutaneous wounds and 
misapplication can be easily corrected with the application of acetone [2] Other 
synthetic mechanical adhesives such as polyethylene glycol hydrogels and glutaral-
dehyde cross-linked albumin are primarily used in cardiac surgery [2].
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3.7 Hemostatic dressings
Chitin is present naturally in arthropod skeletons [2]. When applied to wounds, 
it causes vasoconstriction, seals the wound, and can be removed with saline if 
applied incorrectly [2]. Of note, these products should be avoided in patients with 
allergy to shellfish [2]. Mineral zeolite is an inexpensive and stable dressing that 
contains inert minerals and absorbs liquid via an exothermic process to increase the 
concentration of coagulation factors [2]. Chitin and mineral zeolite are easily stored 
[2]. Dry fibrin dressing is freeze-dried thrombin and fibrinogen contained on gauze 
[2]. It can be rapidly applied to wounds but has a high cost [2].
3.8 Electrosurgery
Electrosurgery is the use of alternating high frequency current to obtain hemo-
stasis [3]. The effect on tissue depends on the type of device, waveform, and type 
of electrode [3]. An understanding of terminology is important for appropriate 
use. Monoterminal refers to the use of low power current that disperses to the 
environment and does not require grounding [3]. Biterminal passes current through 
the tip and patient, into a grounded electrode and back to the power source [3]. 
Monopolar allows both coagulation and cutting modes through a single electrode. 
Bipolar delivers energy current via two electrodes [3]; the two electrodes in the 
bipolar cautery are located close together and result in decreased depth of tissue 
injury [3]. Electrocautery refers to thermal energy causing hemostasis [3]. This 
method is usually used in patients with implanted cardiac defibrillators (IDC) 
due to no current delivered to the patient [3]. Of note, there is a risk of direct 
thermal injury to the ICD if electrocautery is performed at the site of implanta-
tion [3]. Electrodessication, also known as hyfrecation, utilizes a monoterminal, 
high frequency, low amperage current to induce slow heating of tissue close to the 
tip, causing fluid loss of local and superficial “mummification” [3]. In electroful-
guration, the electrode delivers high frequency, low amperage current through a 
monoterminal circuit [3]. The ionization of the surrounding air creates a localized 
“spark” without directly contacting the tissue and causes localized coagulation and 
barrier formation [3]. Electrocoagulation (Bovie) uses a biterminal circuit to cause 
cutting, coagulation, or a mix of both, while electrosection uses a biterminal circuit 
to cut and vaporize tissue with little damage to adjacent tissue. Electrosection is 
rarely used in dermatologic surgery [3].
3.9 Sutures
Sutures play an important role in hemostasis. The type of suture and placement 
is determined by the size of the wound, the location on the body, and type of repair 
performed. While most absorbable sutures are synthetically derived, surgical gut 
suture is created from collagen derived from sheep or cow intestines [4]. Surgical 
gut suture are multifilament sutures subdivided into plain, fast absorbing, and 
chromic [4]. They have low tensile strength ranging from 3–7 days for fast absorb-
ing, 7–10 for plain, and 10–21 days for chromic gut sutures [4]. Time to complete 
absorption may be variable, and tissue reactivity and allergy are disadvantages to 
their use [4].
Surgical silk is the only naturally derived, nonabsorbable suture material [4]. It 
is created from protein fibers harvested from the cocoon of silkworm larva [4]. Its 
excellent knot strength and ease of handling must be weighed against low tensile 
strength and high potential for tissue reactivity [4]. Although it is classified as 
nonabsorbable, it is slowly absorbed over the course of two years [4].
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4. Biosurgical agents in wound care
While dermatologic surgery involves outpatient procedures with minimal blood 
loss, appropriate wound care is necessary for optimized healing. Benign lesions such 
as cysts and lipomas typically heal with minimal scarring after removal [1]. Skin 
cancer excisions and Mohs Micrographic surgery can result in large and irregularly 
shaped defects where complete re-approximation is not always achievable [5]. The 
resulting closures can be fragile and in cosmetically sensitive areas [5]. Wound care 
of linear closures as well as larger defects is an essential component of successful 
dermatologic surgery outcomes.
There are two types of healing: primary intention and secondary intention [6]. 
Healing by primary intention occurs after a direct side-to-side closure of an incision 
[6]. Healing by secondary intention occurs when a defect is left to heal on its own 
without closure [6]. Defects that heal by primary intention result in minimal scar-
ring [6]. Flaps and grafts attempt to force primary intention healing and thereby 
minimize scarring [6]. Defects that are left to heal by second intention are left 
“open” while the healing process takes place [6].
The surgical site defect can take one of two courses. Acute wounds have no 
underlying healing pathology and heal in a predictable and timely fashion [4, 6]. 
Ideally, all cutaneous surgery lesions heal as acute wounds. Chronic wounds typi-
cally involve underlying pathologic impairment of wound healing [4, 6]. Chronic 
wounds can occur when there are impairments in wound healing and medical 
comorbidities, such as in the elderly population [4, 6]. The implementation of 
biosurgical materials to promote healing depends on the type of wound.
4.1 Dressings
Basic modern wound care consists of wound debridement, packing, topical 
therapy, and dressings. Various forms of biosurgical materials are available in 
wound care and are primarily implemented for chronic or recalcitrant wounds 
[1]. Often derived from biomaterials, dressings physically protect the wound from 
trauma and bacteria, compress the wound to encourage hemostasis, minimize 
fluid and heat loss, and absorb drainage [7]. Acute wounds heal best when they are 
moist, but it is important to minimize maceration or excessive moisture that can 
cause tissue break down [8, 9].
Wound dressings are further broken down as nonadherent, absorptive, and 
occlusive. Nonadherent fabrics can be either hydrophobic, which provide better 
occlusion but worse drainage, or hydrophilic, which provide better drainage but 
worse occlusion [10]. Alginates are a popular biologically derived material used 
for dressings. This cellulose like material is made from seaweed and calcium salts, 
which react with the wound to form a hydrophilic gel [10]. It is a hemostatic, highly 
absorbent, and non-adhesive dressing. It is typically used in deeper wounds [10]. 
Newer materials used as occlusive dressings include collagen and hyaluronic acid. 
Collagen dressings are derived from type I bovine collagen and provide a matrix 
to promote wound healing [10]. They are used primarily for moderately exudative 
and recalcitrant wounds. Hyaluronic acid is an absorbent polymer, also found in the 
skin. As a dressing, it forms a biodegradable hydrophilic gel. It facilitates granula-
tion tissue formation and epithelialization [10].
There is a wide array of commercially available dressings (roughly 3000) that 
include these materials in adhesive, gel, and powder forms [11, 12]. These dressings 
are stored at room temperature with a minimum shelf life of three months, and 
thus, can be implemented with relative ease in an outpatient setting [12].
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4.2 Grafts
Flaps and grafts promote wound healing by primary intention by creating a 
linear closure. They can be considered a type of dressing. A graft is skin separated 
from its blood supply and transferred to a new location [13]. They may be some 
combination of the following: autografts or skin grafts derived from the patient, 
allografts derived from the same species, and xenografts derived from a different 
species. Full thickness grafts contain the epidermis, dermis, and subcutaneous 
tissue. Split thickness grafts consist of just the epidermis and part of the dermis. 
Composite grafts consist of skin as well as cartilage [10].
Grafts can be further delineated as either biologic or biosynthetic. Biologic full 
thickness grafts are usually allografts frequently utilized during Mohs micrographic 
surgery [5]. They are usually derived from the pre- or postauricular area, the inner 
arms, nasolabial folds, or clavicular area [13]. Full thickness grafts are best for 
cosmetically sensitive areas but have a higher risk of failure due to a greater blood 
supply demand [13]. Split thickness grafts can be used for skin cancer removals in 
less cosmetically sensitive areas, such as the lower leg, or in areas with a high risk of 
recurrence [13]. They are usually derived from the donor thigh or buttock [13].
Skin substitutes or biosynthetic grafts are derived from biological materials 
(Table 1) [10]. They are epidermal, dermal, or composite (derived from more 
than one species) [10]. Epidermal grafts include cultured epidermal autograft 
or allograft. Cultured epidermal autografts are epidermal sheets grown from the 
patient and are used for large excisions, chronic ulcers, or severe burns [10]. They 
can cover a large area and often yield good results but take a few weeks to grow 
and are both delicate and expensive [10]. Cultured epidermal allografts are usually 
derived from neonatal foreskin [10]. This skin releases its own growth factors and 
is progressively replaced by the patient skin [10]. These are immediately available 
and help avoid a donor site wound; however, they are expensive and carry a risk 
Type Biological Material
Epidermal
Cultured autografts Epidermal sheets of keratinocytes grown from the patient
Cultured allografts (Epicel) Neonatal foreskin
Dermal
Cryopreserved allografts Cadaver skin
Chemically treated cryopreserved allograft 
(Alloderm)
Cadaver skin with decellularization, matrix stabilization, 
and freeze drying
Porcine derived chemically treated collagen Type I porcine collagen
Bovine collagen chondroitin sulfate over 
silastic (Integra)
Type I bovine collagen and chondroitin 6-sulfate
Fibroblasts in bioabsorbable mesh 
(Dermagraft)
Human neonatal foreskin fibroblasts
Composite
Human keratinocytes layered on bovine 
collagen (Apligraft)




Skin substitute grafts. Adapted from Bello YM, Phillips TJ. Recent advances in wound healing.
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for disease transmission [10]. Cultured epidermal allografts can be used for either 
acute or chronic wounds [10].
There are also a variety of dermal skin substitutes. Cryopreserved allografts 
are derived from cadaver skin and are typically reserved for burns [10]. They are 
immediately available, but they must be kept frozen with a shelf life of up to five 
years [12] and also carry a risk for disease transmission [10]. Chemically treated 
cryopreserved grafts are cadaver grafts that have been treated to remove antigens 
[10]. They therefore carry less risk for rejection but require viral screening [10].
Porcine xenografts are less expensive than their counterparts (refer to Table 1) 
and can be used as temporary dressing or to help re-epithelialize surgical sites [14]. 
Porcine xenografts and cryopreserved allografts have been shown to be equally 
effective clinically [15]. Xenografts have a long shelf-life, may be stored at room 
temperature, and can be rapidly applied to wounds and can be sutured or held in 
place with a dressing [14]. Porcine grafts can also be replaced or removed, perma-
nently grafted, or left to desiccate and fall off as wounds heal [14].
Porcine derived chemically treated collagen is a dermal xenograft skin substitute 
[16]. They are useful because they have a long shelf life, carry no human disease, 
and are immediately available. However, they lack extensive evidence of their 
efficacy [10]. Bovine collagen chondroitin sulfate over silastic is another dermal 
xenograft skin substitute. It works similarly to porcine derived collagen and has a 
shelf life of two years; it is easier to handle than the more fragile grafts but is sus-
ceptible to infection [10]. Fibroblasts in bioabsorbable mesh are allogeneic human 
neonatal foreskin fibroblasts on nylon bioabsorbable mesh. They are advantageous 
because they are immediately available and result in less wound contracture, but 
they are expensive and must be stored in cold temperatures [10].
Composite skin substitutes include human keratinocytes layered on bovine col-
lagen. These do not have the normal skin appendages including nerves and vessels, 
and thus are immunologically inert. They are useful since they are immediately 
available and also easy to handle but only have a shelf life of ten days and are very 
expensive [10].
5. Conclusions
While Dermatologic surgery involves outpatient procedures, adequate hemosta-
sis is important intra- and postoperatively and appropriate wound care is necessary 
for optimized healing. The use of adjunctive materials including biosurgicals to 
promote hemostasis and healing depends on the type of wound, type of bleeding, 
amount of bleeding, and patient factors. Properties of the adjunctive agent affect 
the decision as well, such as speed of hemostasis, ease of application, and tissue 
reactivity.
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